OTHER
Completed Trials:
Investigator Initiated:
Secure the future Apoptosis study
An evaluation of CD4+T cell apoptosis as a surrogate marker for monitoring progression and response to antiretroviral therapy in HIV-1 infected children – a single centre study.
Duration: June 2002 – 2005
Rockefeller
Standard Strategies for prevention of opportunistic infection in HIV infected SA children. Comparison of two Bactrim prophylaxis regimes with and without INH impact on morbidity, mortality, incidence of TB and bacterial resistance.
Duration KIDCRU: 12 December 2002 to 15 September 2004
Duration KIDCRU: March 2009 - October 2011
Duration Paarl: July 2007 – October 2011
HEU
HIV Exposed Uninfected (HEU) Infants have a transient innate immune abnormality and a possible adaptive immune difference. Pilot study: to investigate the innate immune response in HEU and HIV unexposed (UE) infants at 2 and 6 weeks and adaptive immune response at 12 weeks of life. Objectives (1) determine the difference between HEU and UE infants in innate immune function. (2) To determine the significance of this difference. (3) Determine vaccine responses to standard vaccines.
Duration March 2009 – August 2011
IDC Lipodystrophy study
Prospective observational study to determine the prevalence of lipodystrophy among children at the Family Clinic for HIV at Tygerberg.
Duration: January 2010 – June 2012
VPM
Phase II an Open Label, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison with BCG in HIV-unexposed, BCG naive Newborns in South Africa
Duration: November 2011 – November 2012
Current Trials:
MIHS
Prospective cohort study to determine whether in utero HIV exposure is associated with an increased risk of infectious morbidity in HIV exposed uninfected infants; whether there is a difference in severity of infectious morbidity between HIV exposed uninfected and HIV unexposed uninfected infants; and whether the extent of maternal HIV disease is associated with severity of infectious morbidity. Within the cohort, sub-studies will address infant feeding choices, placental pathology and immunology, CMV incidence and infection and toxoplasmosis incidence and infection.
Duration 16 July 2012 – ongoing
DNDi
Pharmacokinetics of lopinavir/ritonavir superboosting in infants and young children co-infected with HIV and TB.
Duration: 2013 - ongoing
